Results 71 to 80 of about 18,010 (199)

Correction to: Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections [PDF]

Drugs, 2018
The article Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections.
openaire   +2 more sources

Boronic Acid Inhibitors of β‐Lactamases: A Promising Strategy Against Antimicrobial Resistance

Medicinal Research Reviews, EarlyView.
ABSTRACT The rise of antimicrobial resistance (AMR) poses a critical threat to global health, mostly due to the proliferation of β‐lactamases, a class of enzymes responsible for the inactivation of β‐lactam antibiotics. Among the most promising strategies to restore β‐lactam efficacy is the use of β‐lactamase inhibitors (BLIs), with boronic acid ...
Nicolò Santi, Federico Corsini, Robert A. Bonomo, Emilia Caselli, Fabio Prati   +4 more
wiley   +1 more source

Mutation of kvrA causes OmpK35/36 porin downregulation and reduced meropenem/vaborbactam susceptibility in KPC-producing Klebsiella pneumoniae [PDF]

, 2020
Meropenem/vaborbactam resistance in Klebsiella pneumoniae is associated with loss of function mutations in the OmpK35 and OmpK36 porins. Here we identify two previously unknown loss of function mutations that confer cefuroxime resistance in K. pneumoniae.
Avison, Matthew B, Wan Ahmad Kamil, Wan Nur Ismah, Douglas, Edward J. A., Avison, Matthew B., Douglas, Edward J A, Dulyayangkul, Punyawee   +5 more
core   +1 more source

Early Experience With Meropenem-Vaborbactam for Treatment of Carbapenem-resistant Enterobacteriaceae Infections [PDF]

Clinical Infectious Diseases, 2019
AbstractTwenty patients with carbapenem-resistant Enterobacteriaceae infections were treated with meropenem-vaborbactam. Thirty-day clinical success and survival rates were 65% (13/20) and 90% (18/20), respectively. Thirty-five percent of patients had microbiologic failures within 90 days.
Ryan K, Shields, Erin K, McCreary, Rachel V, Marini, Ellen G, Kline, Chelsea E, Jones, Binghua, Hao, Liang, Chen, Barry N, Kreiswirth, Yohei, Doi, Cornelius J, Clancy, M Hong, Nguyen   +10 more
openaire   +2 more sources

ARC in Critical Ill OLT Recipients: True Prevalence, Risk Factors, and Impact on Early Aggressive PK/PD Target Non‐Attainment of CI Beta‐Lactam Therapy for Posttransplant Gram‐Negative Infections

Transplant Infectious Disease, EarlyView.
Augmented renal clearance (ARC) represents a quite prevalent condition among critical orthotopic liver transplant recipients (23.2%). ARC is associated with different demographics and clinical features and significantly affects the attainment of aggressive beta‐lactams pharmacokinetic/pharmacodynamic targets despite the administration of standard ...
Milo Gatti, Riccardo De Paola, Matteo Rinaldi, Cristiana Laici, Antonio Siniscalchi, Pierluigi Viale, Federico Pea   +6 more
wiley   +1 more source

Development of an HPLC Method for the Determination of Meropenem/Vaborbactam in Biological and Aqueous Matrixes

Journal of Chromatographic Science, 2020
Abstract A HPLC method was developed and validated to analyze meropenem and vaborbactam simultaneously in murine plasma and saline matrixes. A 60-μL volume of extracted sample was injected onto a 5-μm BDS Phenyl-Hypersil C18 reversed-phase column and analyzed with a UV detector set at 298 nm for the first 4.9 min and switched to 240 nm ...
Christina A, Sutherland, David P, Nicolau   +1 more
openaire   +2 more sources

Successful Rapid Desensitization to Ceftazidime/Avibactam in a Patient With Cystic Fibrosis and Multidrug‐Resistant Pseudomonas aeruginosa Pneumonia: A Case Report

Clinical Case Reports, Volume 14, Issue 8, August 2026.
ABSTRACT Ceftazidime/avibactam (CAZ‐AVI) is an important therapeutic option for multidrug‐resistant (MDR) Pseudomonas aeruginosa infections; however, hypersensitivity reactions may preclude its use and create significant therapeutic challenges. We report a 21‐year‐old woman with cystic fibrosis and recurrent MDR P.
Zuoren Zhou, Jinqi Zhu, Ge Wu, Xi Kang, Qing Wang, Jie Liu, Yan Jiang   +6 more
wiley   +1 more source

Meropenem–vaborbactam: a new weapon in the war against infections due to resistant Gram-negative bacteria

, 2018
Meropenem–vaborbactam is a fixed-dose combination product of a carbapenem and a cyclic boronic acid β-lactamase inhibitor with potent in vitro activity against Klebsiella pneumoniae carbapenemase-producing carbapenem-resistant Enterobacteriaceae (CRE ...
John P Mills, Twisha S Patel, Jason M Pogue, Keith S Kaye   +3 more
core   +1 more source

Combination of Oral Doxycycline and Rifampin for Pan‐Drug Resistant Klebsiella pneumoniae Infection: A Case Report

Clinical Case Reports, Volume 14, Issue 8, August 2026.
ABSTRACT Pan‐drug resistant Klebsiella pneumoniae is a major therapeutic challenge, particularly when standard last‐line agents are unavailable or contraindicated. We report a 45‐year‐old man with multifocal osteomyelitis and persistent purulent wound discharge despite broad‐spectrum antibiotics, repeated debridement, and two sequential amputations ...
Ali Akbar Heydari, Sepideh Elyasi, Farshad Abedi   +2 more
wiley   +1 more source

Activity of meropenem-vaborbactam against different beta-lactamase producing Klebsiella pneumoniae and Escherichia coli isolates in Iran [PDF]

, 2022
We evaluated the activity of meropenem-vaborbactam against different beta-lactamase producing Klebsiella pneumoniae and Escherichia coli isolates.
Nikkhahi, Farhad, Peymani, Amir, Aali, Ehsan, Farhad Nikkhahi, Fatemeh Zeynali Kelishomi, Amir Peymani, Fatemeh Fardsanei, Fardsanei, Fatemeh, Zeynali kelishomi, Fatemeh, Ghayaz, Fatemeh, Kelishomi, Fatemeh Zeynali, Ehsan Aali, Javadi, Amir, Samira Amereh, Fatemeh Ghayaz, Amir Javadi, Amereh, Samira   +16 more
core   +1 more source